Free Daily Podcast Summary
Decera Clinical Education Oncology Podcast: Daily Summaries Delivered
by Decera Clinical Education
Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 1 weeks ago35 min
Evolving Role of B7-H3–Directed ADCs in the Extensive-Stage Small-Cell Lung Cancer Treatment Landscape
In this podcast episode, Charles Rudin, MD, PhD, and Mark A. Socinski, MD, discuss current gaps and clinical needs for patients with relapsed ES-SCLC, and the evolving role of B7-H3–directed antibody–drug conjugates in the management of patients with ES-SCLC, including:Clinical needs for relapsed ES-SCLCScientific rationale for targeting B7-H3 and other tumor-associated antigens in SCLCADCs, T-cell engagers, chemotherapy-based approaches, maintenance strategies, and ongoing clinical trials for ES-SCLCRecent efficacy and safety data for B7-H3–directed ADCs in ES-SCLC, including I-DXdPersonalization of care of patients with SCLC, including patient-specific factors influencing treatmentCase discussion of a patient with ES-SCLC requiring optimal next best treatmentImportance of enrolling patients in ongoing trials of investigational agents for patients with ES-SCLCPresenters:Charles Rudin, MD, PhDCancer Center DirectorMemorial Sloan Kettering Cancer CenterNew York, New YorkMark A. Socinski, MDExecutive Medical DirectorAdventHealth Cancer InstituteOrlando, FloridaLink to full program:https://bit.ly/3UBEeYz Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
- 2 weeks ago29 min
Targeting CDH6 in Platinum-Resistant Ovarian Cancer: Emerging ADCs, Biomarkers, and Sequencing
In this podcast episode, BJ Rimel, MD, and Elizabeth Lee, MD, discuss the scientific rationale for targeting CDH6 in ovarian cancer and the emerging role of CDH6-directed antibody–drug conjugates (ADCs) in platinum-resistant disease, including:CDH6 biology, expression patterns, and its potential as a therapeutic target in ovarian cancerEarly-phase efficacy data with investigational CDH6-directed ADCs, including raludotatug deruxtecan (R-DXd) and CUSP06, and an ongoing phase III trial of R-DXdSafety considerations with CDH6-directed ADCs, including cytopenias, gastrointestinal toxicities, fatigue, and interstitial lung disease/pneumonitisConsiderations for sequencing ADCs, including the potential impact of target expression, payload class, and mechanisms of resistancePresenters:BJ Rimel, MDDivision Chief, Gynecologic OncologyProfessor, Department of OB/GYNUniversity of WashingtonClinical Director of Gynecologic OncologyFred Hutchinson Cancer CenterSeattle, WashingtonElizabeth Lee, MDDivision of Gynecologic OncologyCenter for Cancer Therapeutic InnovationDepartment of Medical OncologyDana-Farber Cancer InstituteBoston, MassachusettsLink to full program: https://bit.ly/3SqCAZ6Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
- 2 weeks ago9 min
ASCO 2026 Updates in Early Hormone Receptor–Positive Breast Cancer
In this podcast episode, Hope S. Rugo, MD, FASCO, and Nerea Lopetegui-Lia, MD, discuss practice-informing data presented at ASCO 2026 for patients with early-stage hormone receptor (HR)–positive/HER2-negative breast cancer, including:Findings from the OPTIMA trial evaluating Prosigna gene expression testing to guide adjuvant chemotherapy decisions in patients with high-risk HR-positive/HER2-negative early breast cancerThe importance of ovarian function suppression plus endocrine therapy when considering chemotherapy-sparing strategies in premenopausal patientsResults from the NATALEE PAM50 biomarker analysis, showing ribociclib benefit across intrinsic subtypes with no significant treatment-by-subtype interactionPresenters:Hope S. Rugo, MD, FASCODirector, Women’s Cancer ProgramDivision Chief, Breast Medical OncologyProfessor, Department of Medical Oncology & Therapeutics ResearchCity of Hope Comprehensive Cancer CenterProfessor Emeritus and Emeritus Winterhof Family Distinguished Professor of Breast OncologyUniversity of California, San FranciscoSan Francisco, CaliforniaNerea Lopetegui-Lia, MDAssistant ProfessorDivision of Medical Oncology, Breast SectionDepartment of Internal MedicineThe Ohio State UniversityColumbus, OhioGet access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify.Link to full program: https://bit.ly/4x4u5AT Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
- 3 weeks ago22 min
CELMoDs on the Horizon: A New Chapter in Lymphoma Care
Treatment options for patients with lymphoma are rapidly evolving. In this podcast episode, Alex F. Herrera, MD, and Marc Hoffmann, MD, discuss cereblon E3 ligase modulators (CELMoDs) as potential treatment options for patients with aggressive diffuse large B-cell lymphoma and follicular lymphoma, with a focus on golcadomide, an investigational, oral, first-in-class CELMoD therapy. Topic areas covered include: Biologic and clinical rationale for the use of CELMoD therapy in lymphoma patients Emerging clinical trial data on golcadomide alone and in combination with other regimens Real-world expectations for incorporating CELMoD-based therapies into community lymphoma care settings such as efficacy, patient selection, and toxicity management strategies Presenters: Alex F. Herrera, MD Chief, Division of Lymphoma Professor, Department of Hematology and Hematopoietic Cell Transplantation Director, Toni Stephenson Lymphoma Center City of Hope Duarte, California Marc Hoffmann, MD Director, Lymphoma Program Medical Director, Lean and Quality Improvement Associate Professor Division of Hematologic Malignancies and Cellular Therapeutics University of Kansas Cancer Center Kansas City, Kansas Content based on an online CME program supported by an educational grant from Bristol Myers Squibb. Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Link to CME: Claim Credit Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
- Aug 20, 202613 min
Experts Discuss Health Disparities and Equitable Care Strategies in Multiple Myeloma
In this podcast episode, Jesus G. Berdeja, MD, and Ajai Chari, MD, discuss health disparities and equitable care strategies in multiple myeloma, including: Treatment for underserved populations Navigating REMS for novel therapeutics Clinical trial design and enrolment Presenters:Jesus G. Berdeja, MD Director of Myeloma Research Greco-Hainsworth Centers for Research Partner Tennessee Oncology Nashville, Tennessee Ajai Chari, MD Professor of Clinical Medicine Director of Multiple Myeloma Program UCSF Helen Diller Family Comprehensive Cancer Center University of California, San Francisco (UCSF) Medical Center San Francisco, California Content based on an online CME program supported by an educational grant from GSK. Link to full program:https://bit.ly/3TZSmuf Get access to all of our new podcasts by subscribing tothe Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
- Aug 20, 202626 min
Experts Discuss CELMoD Agents for Multiple Myeloma
In this podcast episode, Meletios-Athanasios (Thanos) C. Dimopoulos, MD, and María-Victoria Mateos, MD, PhD, as they discuss the use of CELMoD agents to manage multiple myeloma, including: The recent FDA approval of iberdomide Mechanism of action and differentiation from IMiDs Current data and potential treatment settings Presenters:Meletios-Athanasios (Thanos) C. Dimopoulos, MD Professor and Chairman Plasma Cell Dyscrasias Unit Section of Hematology and Medical Oncology Department of Clinical Therapeutics School of Medicine National and Kapodistrian University of Athens Alexandra Hospital Athens, Greece María-Victoria Mateos, MD, PhD Myeloma Unit, Director Professor of Medicine University Hospital of Salamanca Salamanca, Spain Content based on an online CME program supported by an educational grant from Bristol Myers Squibb. Link to full program:https://bit.ly/4xgnHri Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
- Aug 14, 202632 min
Optimizing Oral Targeted Therapies for HR+/HER2- Breast Cancer
In this episode, Danielle Roman, PharmD, BCOP, and Jordan Hill, PharmD, BCOP, discuss optimal care for patients with HR-positive/HER2-negative breast cancer receiving newer oral targeted therapies. Their conversation addresses treatment selection across early-stage and metastatic disease, biomarker-informed decision-making, adverse event management, and practical strategies to help patients remain on therapy. Key topics include: Selecting and sequencing oral targeted therapies, including CDK4/6 inhibitors, PARP inhibitors, PI3K/AKT pathway inhibitors, and oral SERDs Identifying patients with high-risk early breast cancer and applying evidence from trials such as monarchE, NATALEE, and OlympiA Using biomarkers such as BRCA1/2, PIK3CA, AKT1, PTEN, and ESR1 to guide therapy in metastatic disease Monitoring and managing treatment-related adverse events, including neutropenia, diarrhea, hepatotoxicity, QTc prolongation, hyperglycemia, rash, stomatitis, anemia, nausea, and fatigue Using dose modification, supportive care, patient education, and proactive follow-up to improve adherence and persistence with oral therapy Incorporating oncology pharmacists and the multidisciplinary care team into ongoing treatment monitoring and patient support PresentersDanielle Roman, PharmD, BCOP Manager, Oncology Clinical Pharmacy Services Oncology Clinical Pharmacy Specialist Allegheny Health Network Pittsburgh, Pennsylvania Jordan Hill, PharmD, BCOP Clinical Pharmacy Specialist, Breast Oncology West Virginia University Cancer Institute Morgantown, West Virginia Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Access the full educational program: Link to full program:https://bit.ly/4gvZerW And be sure to try our Interactive Decision Support Tools for Early Breast Cancer and Selecting AKT or PI3K Inhibitors for Patients With Metastatic Breast Cancer. By answering just a few quick questions, you can see what 5 experts would recommend for specific patient scenarios. Early Breast Cancer:https://bit.ly/4gtUiUq AKT or PI3K Inhibitors in MBC:https://bit.ly/4qcyBvk Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
- Aug 13, 202636 min
TGCT Today: Understanding Diagnosis, Treatment, and Long-term Care
Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive disease that can cause chronic pain, joint dysfunction, reduced mobility, and significant impacts on quality of life, particularly in patients with diffuse disease. In this expert discussion, Dr William Tap and Dr Emanuela Palmerini explore the evolving management of TGCT, including the biologic role of the CSF1/CSF1R pathway, challenges in diagnosis and disease monitoring, and the importance of multidisciplinary, patient-centered care. They also discuss the growing role of CSF1R-targeted therapies, treatment selection, toxicity management, drug holidays, and practical approaches to optimizing long-term outcomes for patients living with TGCT. Topics Covered Understanding localized vs diffuse TGCT Biology of the CSF1/CSF1R pathway Diagnostic approaches and the role of MRI and biopsy Multidisciplinary care and shared decision-making Impact of TGCT on function, mobility, and quality of life Current and emerging CSF1R-targeted therapies Pexidartinib and vimseltinib: clinical considerations and toxicity management Response assessment beyond imaging Drug holidays, retreatment strategies, and long-term follow-up Future directions in TGCT research and treatment Faculty William Tap, MD Emanuela Palmerini, MD, PhD Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Get Decera Clinical Education Oncology Podcast summaries in your inbox
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
You Might Also Like
Listeners also like.
Out of the Gray (Gy) - Standard Imaging
Conversations with experts in radiation oncology exploring advancements in technology, research, and clinical practice.
The Curbsiders Internal Medicine Podcast
Expert-led internal medicine discussions with clinical insights and humor for primary care and hospital medicine providers.
Health Discovered
Doctors explore surprising stories to uncover insights about health and well-being.
Red Pill Your Healthcast
Two healthcare providers discuss overlooked health issues and empower listeners to make informed decisions for their families.
This Week in Cardiology
A weekly summary and analysis of key developments in cardiology for healthcare professionals.
The Clinical Problem Solvers
Experts discuss diagnostic reasoning in clinical medicine.
Psychiatry & Psychotherapy Podcast
Explores psychiatry and psychotherapy through interviews with experts, trainees, and individuals sharing lived mental health experiences.
Treated with Dr. Sara Szal
Dr. Sara Szal explores holistic health solutions through conversations with experts and patients seeking mind, body, and soul healing.
The Curious Clinicians
A medical podcast exploring the underlying mechanisms of diseases, treatments, and human physiology through curious inquiry.
Health Optimization Medicine Podcast
Experts discuss health optimization, performance, and decision-making with insights from neuroscience, medicine, and consciousness.
The Internet Book of Critical Care Podcast
A podcast exploring critical care medicine through chapter discussions and evidence-based updates from The Internet Book of Critical Care.
SHE MD
Candid discussions on women’s health topics like fertility, menopause, and PCOS with expert insights from an OBGYN and a women’s advocate.
About Decera Clinical Education Oncology Podcast
Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from Decera Clinical Education Oncology Podcast in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's Decera Clinical Education Oncology Podcast daily summary?
It's a free AI-powered email that summarizes new episodes of Decera Clinical Education Oncology Podcast as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the Decera Clinical Education Oncology Podcast podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official Decera Clinical Education Oncology Podcast product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Decera Clinical Education.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
How often does Decera Clinical Education Oncology Podcast release new episodes?
Decera Clinical Education Oncology Podcast publishes 2x weekly. Our AI generates a summary within hours of each new episode.
What topics does Decera Clinical Education Oncology Podcast cover?
Decera Clinical Education Oncology Podcast covers topics including Science, Education, Courses, Medicine, Fitness, Health & Fitness, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting Decera Clinical Education Oncology Podcast summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.